alanine has been researched along with Latent Tuberculosis in 1 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Latent Tuberculosis: The dormant form of TUBERCULOSIS where the person shows no obvious symptoms and no sign of the causative agent (Mycobacterium tuberculosis) in the SPUTUM despite being positive for tuberculosis infection skin test.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Short-course preventive therapy with 1-month course of daily administration of isoniazid (300-mg) plus rifapentine (600-mg) (1HP) and 3-month course of weekly administration of isoniazid (900-mg) plus rifapentine (900-mg) (3HP) has higher completion rates than 9-month course of daily isoniazid (9H) for individuals with latent tuberculosis infection (LTBI)." | 8.02 | Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide. ( Cheng, CN; Chuang, YC; Hung, CC; Kuo, CH; Lin, KY; Lin, SW; Lin, YJ; Lin, YT; Liou, BH; Liu, WC; Sun, HY, 2021) |
| "Short-course preventive therapy with 1-month course of daily administration of isoniazid (300-mg) plus rifapentine (600-mg) (1HP) and 3-month course of weekly administration of isoniazid (900-mg) plus rifapentine (900-mg) (3HP) has higher completion rates than 9-month course of daily isoniazid (9H) for individuals with latent tuberculosis infection (LTBI)." | 4.02 | Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide. ( Cheng, CN; Chuang, YC; Hung, CC; Kuo, CH; Lin, KY; Lin, SW; Lin, YJ; Lin, YT; Liou, BH; Liu, WC; Sun, HY, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liou, BH | 1 |
| Cheng, CN | 1 |
| Lin, YT | 1 |
| Lin, YJ | 1 |
| Chuang, YC | 1 |
| Lin, KY | 1 |
| Liu, WC | 1 |
| Lin, SW | 1 |
| Kuo, CH | 1 |
| Sun, HY | 1 |
| Hung, CC | 1 |
1 other study available for alanine and Latent Tuberculosis
| Article | Year |
|---|---|
Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infect | 2021 |